LGT Fund Management Co Ltd. Raises Stake in Boston Scientific Corporation $BSX

LGT Fund Management Co Ltd. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 61.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 95,955 shares of the medical equipment provider’s stock after buying an additional 36,611 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Boston Scientific were worth $6,021,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Associated Banc Corp grew its position in shares of Boston Scientific by 28.5% during the 1st quarter. Associated Banc Corp now owns 480,358 shares of the medical equipment provider’s stock valued at $30,142,000 after acquiring an additional 106,526 shares during the period. ARQ Wealth Advisors LLC bought a new stake in shares of Boston Scientific in the 1st quarter worth approximately $408,000. Diversify Wealth Management LLC lifted its stake in Boston Scientific by 96.7% in the first quarter. Diversify Wealth Management LLC now owns 12,735 shares of the medical equipment provider’s stock valued at $728,000 after purchasing an additional 6,262 shares during the last quarter. 180 Wealth Advisors LLC grew its holdings in Boston Scientific by 3.6% during the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after purchasing an additional 223 shares during the period. Finally, Cullinan Associates Inc. grew its holdings in Boston Scientific by 91.9% during the first quarter. Cullinan Associates Inc. now owns 23,799 shares of the medical equipment provider’s stock valued at $1,493,000 after purchasing an additional 11,399 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research reports. UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Leerink Partners cut their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. BTIG Research restated a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Tuesday, June 16th. Jefferies Financial Group cut their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Finally, Bank of America reduced their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.32.

Insider Activity

In other news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded down $0.32 during midday trading on Friday, reaching $44.67. 12,037,584 shares of the company traded hands, compared to its average volume of 18,748,692. The firm’s fifty day moving average price is $49.41 and its two-hundred day moving average price is $67.70. The firm has a market capitalization of $66.40 billion, a price-to-earnings ratio of 18.69, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $42.25 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.